Sino Biopharmaceutical Ltd (SBMFF)
OTHER OTC:SBMFF
SBMFF Stock Chart & Stats
$0.77
-$0.01(-3.00%)
At close: 4:00 PM EST
$0.77
-$0.01(-3.00%)
Day’s Range― - ―
52-Week Range$0.53 - $1.24
Previous CloseN/A
Volume3.69K
Average Volume (3M)511.00
Market Cap
$10.12B
Enterprise Value$79.41B
Total Cash (Recent Filing)$19.82B
Total Debt (Recent Filing)$11.96B
Price to Earnings (P/E)29.5
Beta0.50
Next Earnings
Aug 26, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend Yield1.4%
Share Statistics
EPS (TTM)0.21
Shares Outstanding18,705,018,000
10 Day Avg. Volume800
30 Day Avg. Volume511
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)3.27
Price to Sales (P/S)3.15
P/FCF Ratio13.21
Enterprise Value/Market Cap7.85
Enterprise Value/Revenue2.60
Enterprise Value/Gross Profit3.18
Enterprise Value/Ebitda12.99
Forecast
1Y Price Target
$1.08Price Target Upside39.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.03
Revenue Forecast (FY)$4.58B
Bulls Say, Bears Say
Bulls Say
High Gross ProfitabilitySustained gross margins near 78%–83% indicate durable product-level pricing power and cost structure advantages. This supports resilient operating earnings and shields profitability from moderate cost inflation, enabling sustained reinvestment in R&D and commercialization over the medium term.
Re-accelerating Revenue GrowthTop-line re-acceleration in 2025 shows improving commercial traction and product adoption. Stronger revenue momentum expands scale, enhances fixed-cost absorption and provides a firmer base for sustained investment in pipeline expansion and market penetration over the next several quarters.
Robust Cash GenerationRising operating and free cash flow with FCF-to-net-income ~0.82 indicates quality earnings and strong cash conversion. Reliable cash generation supports internal funding for R&D and commercialization, reduces reliance on external capital, and provides flexibility through business cycles.
Bears Say
Declining Net MarginA material drop in net margin compresses retained earnings and undermines returns on capital. If persistent, weaker net profitability limits ability to self-fund growth, reduces cushioning against shocks, and raises the bar for sustaining investments in higher-cost specialty franchises.
Rising Financial LeverageMeaningful increase in debt-to-equity tightens financial flexibility and raises refinancing and interest-rate exposure. With profitability under pressure, higher leverage increases strain on cash flow coverage and could force trade-offs between debt servicing and investing in R&D or commercialization.
Exposure To China Reimbursement PressureRevenue and pricing are materially influenced by China's reimbursement and centralized procurement policies. Structural shifts or tougher procurement pricing can erode margins and volumes for hospital-facing prescription drugs, creating persistent revenue and pricing risk for the business model.
Sino Biopharmaceutical News
SBMFF FAQ
What was Sino Biopharmaceutical Ltd’s price range in the past 12 months?
Sino Biopharmaceutical Ltd lowest stock price was $0.53 and its highest was $1.24 in the past 12 months.
What is Sino Biopharmaceutical Ltd’s market cap?
Sino Biopharmaceutical Ltd’s market cap is $10.12B.
When is Sino Biopharmaceutical Ltd’s upcoming earnings report date?
Sino Biopharmaceutical Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 63 days.
How were Sino Biopharmaceutical Ltd’s earnings last quarter?
Sino Biopharmaceutical Ltd released its earnings results on Mar 26, 2026. The company reported $0.001 earnings per share for the quarter, missing the consensus estimate of $0.009 by -$0.007.
Is Sino Biopharmaceutical Ltd overvalued?
According to Wall Street analysts Sino Biopharmaceutical Ltd’s price is currently Undervalued.
Does Sino Biopharmaceutical Ltd pay dividends?
Sino Biopharmaceutical Ltd pays a Quarterly dividend of $0.006 which represents an annual dividend yield of 1.4%. See more information on Sino Biopharmaceutical Ltd dividends here
What is Sino Biopharmaceutical Ltd’s EPS estimate?
Sino Biopharmaceutical Ltd’s EPS estimate is 0.02.
How many shares outstanding does Sino Biopharmaceutical Ltd have?
Sino Biopharmaceutical Ltd has 18,705,018,000 shares outstanding.
What happened to Sino Biopharmaceutical Ltd’s price movement after its last earnings report?
Sino Biopharmaceutical Ltd reported an EPS of $0.001 in its last earnings report, missing expectations of $0.009. Following the earnings report the stock price went down -3.034%.
Which hedge fund is a major shareholder of Sino Biopharmaceutical Ltd?
Currently, no hedge funds are holding shares in SBMFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sino Biopharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.08 (39.86% Upside)
$1.08 (39.86% Upside)
Insider Transactions
Bought Shares
Worth $8.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.71%
12-Months-Change
Fundamentals
Return on Equity
7.24%
Trailing 12-Months
Asset Growth
21.38%
Trailing 12-Months
Company Description
Sino Biopharmaceutical Ltd
Established in 2000 and headquartered in Wan Chai, Hong Kong, Sino Biopharmaceutical Limited functions as an investment holding entity overseeing a prominent research and development-focused pharmaceutical conglomerate. Its core operations are primarily situated within the People's Republic of China, segmented into three main areas: modern and traditional Chinese medicines and chemical pharmaceuticals, investment ventures, and other diverse activities. The company maintains an extensive portfolio of pharmaceutical products addressing numerous therapeutic categories. This includes oncology treatments such as Qingkeshu tablets and Anxian capsules; cardiovascular and cerebrovascular medications like Kaina and Anrixin tablets; hepatitis remedies, including Tianqingganmei injections; and orthopedic solutions such as Gaisanchun capsules. The product range also covers respiratory system drugs, parenteral nutritional therapies (e.g., Xinhaineng injections), and other miscellaneous medicines like Tuotuo tablets. Furthermore, Sino Biopharmaceutical distributes a selection of advanced pharmaceuticals, including Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. Beyond pharmaceutical manufacturing and distribution, the company engages in a broad array of healthcare-related services and investments. These activities encompass managing property assets, retailing and distributing pharmaceutical goods, offering optometry services and selling ophthalmic products, and operating hospitals. It also provides medical management and health information consultancy, bio-tech transfer and advisory services, and manufactures and markets health food products. Additionally, the company performs orthopedic outpatient and surgical procedures, develops medical and health technologies, trades optical glasses, and conducts research, development, and sales of medical devices and active pharmaceutical ingredients.
SBMFF Stock 12 Month Forecast
Average Price Target
$1.08
▲(39.86% Upside)
Technical Analysis
Innovent Biologics
―
3SBio
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Ownership Overview
15.77% Insiders
2.91% Mutual Funds
<0.01% Other Institutional Investors
75.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---